R. Romiti, P. Pancheri - Vol. 5, Giugno 1999, num.2
Testo Immagini Bibliografia Summary Riassunto Indice
Le depressioni moderate a componente
ansiosa:
un target terapeutico specifico per venlafaxina a Rilascio
Moderate depression with an ansious
component:
a specific therapeutic target for venlafaxine-extended
1 Pancheri P.
La specificità terapeutica delle molecole antidepressive.
In: Pancheri P, Cassano GB, a cura di. Specificità e aspecificità terapeutica
dei farmaci antidepressivi. Firenze: Scientific Press 1995.
2 Heninger GR, Charney DS.
Mechanism of action of antidepressant treatments. Implications for the
etiology and treatment of depressive disorders.
In: Meltzer HY, ed. Psychopharmacology: The third Generation in Progress.
New York: Raven Press 1987:535-544.
3 Wolfe BB, Harden TK, Sporn JR, Molinoff PB.
Presynaptic modulation of b-adrenergic receptors in rat cerebral cortex
after treatment with antidepressants.
Journal of Pharmacology and Experimental Therapeutics 1978;207:446-457.
4 Moyer JA, Muth EA, Haskins JT, Lappe RW, Sigg EB.
In vivo antidepressant profiles of the novel bicyclic compounds Wy-45,030
and Wy-45,881.
Society for Neuroscience (abstract n. 76.12) 1984:261.
5 Baron BM, Ogden AM, Siegel BW, Stegeman J, Ursillo RC, Dudley MW.
Rapid downregulation of b-adrenoceptor by co-administration of desipramine
and fluoxetine.
European Journal of Pharmachology 1988;154:125-134.
6 Mendels J, Johnston R, Mattes J, Riesenberg R.
Efficacy and safety of b.i.d. doses of venlafaxine in dose-response study.
Psychopharmacology Bullettin 1993;29:169-174.
7 Schweizer E, Weise C, Clary C, Fox I, Richels K.
Placebo-controlled trial of venlafaxine for treatment of major depression.
Journal of Clinical Psychopharmacology 1991;11:233-236.
8 Rudolph R, Entsuah R, Derivan A.
Early clinical response in depression to venlafaxine hydrochloride.
Biological Psychiatry (abstract n. P-26-12) 1991;29:630S.
9 Schweizer E, Feighner J, Mandos LA, Richels K.
Comparison of venlafaxine and imipramine in the acute treatment of major
depression in outpatients.
Journal of Clinical Pstchiatry 1994;55:104-108.
10 Samuelian JC, Tatossian A, Hackett D.
A randomized, double-blind, parallel group comparison of venlafaxine and
clomipramine in outpatients with major depression.
Clinical Neuropharmacology (abstract) 1992;15(Suppl.1):324B.
11 Dierick M, Martin A, Ravizza L, Realini R.
A double-blind comparison of venlafaxine aand fluoxetine for treatment
of major depression in outpatients.
Prog Neuro-Psychopharmacology 1995 (in press).
12 Guelfi JD, White C, Magni.
A double-blind comparison of venlafaxien and placebo in inpatients with
major depression and melancholia.
Clinical Neuropharmacology 1992;15(Suppl.1):323B.
13 Troy SM, Dilea C, Martin PT, Leister CA, Fruncillo RJ, Chiang ST.
Pharmacokinetics of once-daily venlafaxine extended release in healthy
volunteers.
Current Therapeutic Research 1997;58:504-514.
14 Klamerus JK, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST.
Introduction of a composite parameter to the pharmacokinetics of venlafaxine
and its active O-desmethyl metabolite.
Journal of Clinical Pharmacology 1992;32:716-724.
15 Thase ME.
Efficacy and tolerability of once-daily Venlafaxine extended release (XR)
in outpatients with major depression.
Journal of Clinic Psychiatry 1997;58:393-398.
16 Cunningham LA.
Once-daily Venlafaxine extended release (XR) and Venlafaxine immidiate
release (IR) in outpatients with major depression.
Annals of Clinical Psychiatry 1997;9:157-164.
17 Iskandar H, Silverstone P.
Efficacy and tolerability of once-daily venlafaxine XR vs fluoxetine in
depressed outpatients with concomitant anxiety.
European Neuropsychopharmacology 1997;(Suppl.2):S67-S308.
18 Salinas E.
Once-daily venlafaxine XR versus paroxetine in outpatients with major depression.
Collegium Internationale Neuro-Psychopharmacologicum (CINP), Glasgow, July,
1998.
19 Rudolph RL, Entsuah R, Chitra R.
A meta-analysis of the effects of venlafaxine on anxiety associated with
depression.
Journal of Clinical Psychopharmacology 1998;18:136-144.
20 Khan A, Upton V, Rudolph RL, Entsuah R, Leventer SM.
The use of venlafaxine in the tretment of majior depression associated
with anxiety: a dose-response study.
Journal of Clinical Psychopharmacology 1998;18:19-25.
21 Feighner JP, Entsuah R, McPherson MK.
Efficacy of once-daily venlafaxine extended release (XR) for symptoms of
anxiety in depressed outpatients.
Journal of Affective Disorders 1998;47:55-62.
22 Silverstone P, Ravindran A.
Once-daily Venlafaxine extended release (XR) compared with fluoxetine in
outpatients with depression and anxiety.
Journal of Clinic Psychiatry 1999;60:22-28.
23 Data on file, Wyeth Ayerst Research (GMR for 600B-367-EU).
24 Haskins JT, Aguilar L, Pallay A, Rudolph R.
Double-blind, placebo-controlled study of once daily venlafaxine XR in
outpatients with generalized anxiety disorder.
European Neuropsychopharmacology 1998;(Suppl.2):S257.
25 Haskins JT, Rudolph R Aguilar L, Entsuah R, Salinas E.
Venlafaxine XR (V-VR) is an efficacious short- and long-term treatment
for generalized anxiety disorder (GAD).
European Neuropsychopharmacology 1998;(Suppl.2):S265.
26 Haskins JT, Rudolph R Aguilar L, Entsuah R.
Double-blind, placebo-/comparator-controlled study of once daily venlafaxine
XR (V-XR) and buspirone (Bsp) in outpatients with generalized anxiety disorder
(GAD).
European Neuropsychopharmacology 1998;(Suppl.2):S269.
27 Rudolph RL, Derivan AT.
The safety and tolerability of venlafaxine hidrochloride: Analysis of the
clinical trials database.
Journal of Clinical Psychopharmacology 1996;16(Suppl.2):54S-61S.
28 Hackett D.
Tolerability of once-daily formulation of venlafaxine.
Biological Psychiatry 1997;42(Suppl.):244S.